Advertisement
Screener

Protagonist Therapeutics, Inc (PTGX) Increase (Decrease) in Accounts Payable, Trade

2.8 / 5 stars · 68/120 Roast Me

Protagonist Therapeutics, Inc Increase (Decrease) in Accounts Payable, Trade

Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Accounts Payable, Trade of -$1.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-05

  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$4.90M, a 1406.67% decline year-over-year.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $3.00M, a 142.76% increase year-over-year.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$307.00K.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $2.42M.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for fiscal 2025 was $3.72M, a 342.16% increase from fiscal 2024.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for fiscal 2024 was $842.00K.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for fiscal 2023 was -$2.87M, a 240.24% decline from fiscal 2022.
  • Protagonist Therapeutics, Inc increase (decrease) in accounts payable, trade for fiscal 2022 was $2.04M.
Period endIncrease (Decrease) in Accounts Payable, Trade 3 monthIncrease (Decrease) in Accounts Payable, Trade 6 monthIncrease (Decrease) in Accounts Payable, Trade 9 monthIncrease (Decrease) in Accounts Payable, Trade 12 month
2026-06-30-$4.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$1.90M
10-Q · filed 2026-08-05
-$2.20M
derived: sum of 3 quarters · filed 2026-08-05
$214.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$3.00M
10-Q · filed 2026-05-05
$2.70M
derived: sum of 2 quarters · filed 2026-05-05
$5.11M
derived: sum of 3 quarters · filed 2026-05-05
$5.49M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$307.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$2.11M
derived: sum of 2 quarters · filed 2026-02-25
$2.49M
derived: sum of 3 quarters · filed 2026-08-05
$3.72M
10-K · filed 2026-02-25
2025-09-30$2.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$2.79M
derived: sum of 2 quarters · filed 2026-08-05
$4.03M
10-Q · filed 2025-11-06
$2.60M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$375.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$1.61M
10-Q · filed 2026-08-05
$182.00K
derived: sum of 3 quarters · filed 2026-08-05
-$173.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$1.24M
10-Q · filed 2026-05-05
-$193.00K
derived: sum of 2 quarters · filed 2026-05-05
-$548.00K
derived: sum of 3 quarters · filed 2026-05-05
-$746.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$1.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$1.78M
derived: sum of 2 quarters · filed 2026-02-25
-$1.98M
derived: sum of 3 quarters · filed 2026-02-25
$842.00K
10-K · filed 2026-02-25
2024-09-30-$355.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$553.00K
derived: sum of 2 quarters · filed 2025-11-06
$2.27M
10-Q · filed 2025-11-06
$1.68M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$198.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$2.63M
10-Q · filed 2025-08-06
$2.03M
derived: sum of 3 quarters · filed 2026-02-25
-$1.17M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$2.83M
10-Q · filed 2025-05-06
$2.23M
derived: sum of 2 quarters · filed 2026-02-25
-$976.00K
derived: sum of 3 quarters · filed 2026-02-25
-$424.00K
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$597.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$3.80M
derived: sum of 2 quarters · filed 2026-02-25
-$3.25M
derived: sum of 3 quarters · filed 2026-02-25
-$2.87M
10-K · filed 2026-02-25
2023-09-30-$3.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$2.65M
derived: sum of 2 quarters · filed 2024-11-07
-$2.27M
10-Q · filed 2024-11-07
-$3.35M
derived: sum of 4 quarters · filed 2025-02-21
2023-06-30$552.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$933.00K
10-Q · filed 2024-08-06
-$143.00K
derived: sum of 3 quarters · filed 2025-02-21
$3.16M
derived: sum of 4 quarters · filed 2025-02-21
2023-03-31$381.00K
10-Q · filed 2024-05-07
-$695.00K
derived: sum of 2 quarters · filed 2025-02-21
$2.61M
derived: sum of 3 quarters · filed 2025-02-21
-$3.13M
derived: sum of 4 quarters · filed 2025-02-21
2022-12-31-$1.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21
$2.23M
derived: sum of 2 quarters · filed 2025-02-21
-$3.51M
derived: sum of 3 quarters · filed 2025-02-21
$2.04M
10-K · filed 2025-02-21
2022-09-30$3.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
-$2.44M
derived: sum of 2 quarters · filed 2023-11-02
$3.12M
10-Q · filed 2023-11-02
$4.02M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30-$5.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$184.00K
10-Q · filed 2023-08-03
$711.00K
derived: sum of 3 quarters · filed 2024-02-27
-$6.45M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31$5.56M
10-Q · filed 2023-05-04
$6.45M
derived: sum of 2 quarters · filed 2024-02-27
-$705.00K
derived: sum of 3 quarters · filed 2024-02-27
$4.51M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31$895.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
-$6.26M
derived: sum of 2 quarters · filed 2024-02-27
-$1.05M
derived: sum of 3 quarters · filed 2024-02-27
-$1.39M
10-K · filed 2024-02-27
2021-09-30-$7.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$1.94M
derived: sum of 2 quarters · filed 2022-11-08
-$2.29M
10-Q · filed 2022-11-08
-$2.01M
derived: sum of 4 quarters · filed 2023-03-15
2021-06-30$5.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$4.87M
10-Q · filed 2022-08-04
$5.15M
derived: sum of 3 quarters · filed 2023-03-15
$5.11M
derived: sum of 4 quarters · filed 2023-03-15
2021-03-31-$344.00K
10-Q · filed 2022-05-05
-$67.00K
derived: sum of 2 quarters · filed 2023-03-15
-$108.00K
derived: sum of 3 quarters · filed 2023-03-15
-$948.00K
derived: sum of 4 quarters · filed 2023-03-15
2020-12-31$277.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$236.00K
derived: sum of 2 quarters · filed 2023-03-15
-$604.00K
derived: sum of 3 quarters · filed 2023-03-15
$309.00K
10-K · filed 2023-03-15
2020-09-30-$41.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
-$881.00K
derived: sum of 2 quarters · filed 2021-11-03
$32.00K
10-Q · filed 2021-11-03
$1.20M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$840.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$73.00K
10-Q · filed 2021-08-04
$1.24M
derived: sum of 3 quarters · filed 2022-02-28
$71.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$913.00K
10-Q · filed 2021-05-04
$2.08M
derived: sum of 2 quarters · filed 2022-02-28
$911.00K
derived: sum of 3 quarters · filed 2022-02-28
-$2.78M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$2.00K
derived: sum of 2 quarters · filed 2022-02-28
-$3.70M
derived: sum of 3 quarters · filed 2022-02-28
-$3.00M
10-K · filed 2022-02-28
2019-09-30-$1.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
-$4.86M
derived: sum of 2 quarters · filed 2020-11-04
-$4.17M
10-Q · filed 2020-11-04
-$3.35M
derived: sum of 4 quarters · filed 2021-03-10
2019-06-30-$3.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$3.00M
10-Q · filed 2020-08-06
-$2.19M
derived: sum of 3 quarters · filed 2021-03-10
$418.00K
derived: sum of 4 quarters · filed 2021-03-10
2019-03-31$696.00K
10-Q · filed 2020-05-07
$1.51M
derived: sum of 2 quarters · filed 2021-03-10
$4.11M
derived: sum of 3 quarters · filed 2021-03-10
2018-12-31$813.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10
$3.42M
derived: sum of 2 quarters · filed 2021-03-10
$4.43M
10-K · filed 2021-03-10
2018-09-30$2.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$3.62M
10-Q · filed 2019-11-06
2018-06-30$1.01M
10-Q · filed 2019-08-07
2017-12-31$91.00K
10-K · filed 2020-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20